HKSTP
13.1.2021 12:32:31 CET | Business Wire | Press release
Organised by the Innovation and Technology Commission together with the Hong Kong Science and Technology Parks Corporation, the first City I&T Grand Challenge was launched. In light of the new normal under the epidemic, the theme of the competition this year is “Innovating for Hong Kong’s New Normal” and invites all sectors of the community to put forward innovation and technology (I&T) solutions focusing on two issues, namely environmental sustainability and social connectivity, to tackle problems facing the city and people in their daily lives. A series of workshops and other activities will also be held to create an I&T atmosphere in the whole community.
In his video speech for the launch of the event, the Financial Secretary, Mr Paul Chan, said that the Government has allocated over $100 billion in recent years for I&T infrastructure and development. It has provided full support for nurturing I&T talents and fostering an I&T ecosystem. It is committed to improving the entire I&T industry chain from research and development (R&D) to production and marketing, enabling local I&T talents and enterprises to excel. The COVID-19 epidemic has led people to change their old lifestyles and to think about how to solve problems with technology. He believes that the City I&T Grand Challenge will draw creative ideas from all sectors for developing I&T and smart living proposals to help people live as usual and even in a better way in the new normal during and after the epidemic.
The Secretary for Innovation and Technology, Mr Alfred Sit, said in his video address that, in addition to promoting a diversified economy and injecting new impetus into the economy of Hong Kong, an even more important objective for the Government to push forward I&T development is to improve the quality of life, bringing convenience and benefits to members of the public. Describing the City I&T Grand Challenge as an “I&T marathon”, Mr Sit hoped the whole community could take part in and benefit from it. He also hoped that the City I&T Grand Challenge will fuel community-wide enthusiasm for I&T, especially among young people.
Speaking at the media briefing of the competition, the Commissioner for Innovation and Technology, Ms Rebecca Pun, said that, while some business plan competitions put focus on the team members and product development capabilities of a company and its investment prospects, the City I&T Grand Challenge evaluates each proposal based on its originality, uniqueness and effectiveness, application of innovation and technology, as well as social benefits and impact.
Also speaking at the briefing, the Chief Executive Officer of the Hong Kong Science and Technology Parks Corporation, Mr Albert Wong, said that everyone has the potential to be an innovator to shape the future. The City I&T Grand Challenge offers an invaluable opportunity for the public to apply creativity and develop smart solutions catering to the new normal under the epidemic for the benefit of the community.
The City I&T Grand Challenge is open for application from today till 24 April 2021. Target participants range from primary and secondary school students to local and non-local tertiary students, technology enterprises, R&D teams and entrepreneurs. Winners will be awarded a cash prize and a trophy. For the winners of the University and Open categories, they will also have a chance to receive R&D resources and training for refining their I&T solutions for trying at a designated venue such as a government department or a public organisation.
Under each of the focused issues of environmental sustainability and social connectivity, the City I&T Grand Challenge sets up two specific scenarios for participants to select for developing innovative solutions. For “environmental sustainability”, the two scenarios are surrounding disposable plastic tableware and household food waste, which are pressing environmental problems in the new normal. As regards “social connectivity”, the two scenarios are mainly concerned about the physical and social well-being of senior citizens and children under the new normal of social distancing and distant learning.
The website of the City I&T Grand Challenge has been launched for the public to submit applications. A host of workshops, seminars and training activities will also be organised to introduce knowledge on technologies and entrepreneurship as well as topical daily life issues. All are welcome to join. Details are available at the event website (citytechgc.hk ).
*Videos and images are available for download here .
About Hong Kong Science and Technology Parks Corporation
Comprising Science Park, InnoCentre and Industrial Estates, Hong Kong Science & Technology Parks Corporation (HKSTP) is a statutory body dedicated to building a vibrant innovation and technology ecosystem to connect stakeholders, nurture technology talents, facilitate collaboration, and catalyse innovations to deliver social and economic benefits to Hong Kong and the region.
Established in May 2001, HKSTP has been driving the development of Hong Kong into a regional hub for innovation and growth in several focused clusters including Electronics, Information & Communications Technology, Green Technology, Biomedical Technology, Materials and Precision Engineering. We enable science and technology companies to nurture ideas, innovate and grow, supported by our R&D facilities, infrastructure, and market-led laboratories and technical centres with professional support services. We also offer value added services and comprehensive incubation programmes for technology start-ups to accelerate their growth.
Technology businesses benefit from our specialised services and infrastructure at Science Park for applied research and product development; enterprises can find creative design support at InnoCentre; while skill-intensive businesses are served by our three industrial estates at Tai Po, Tseung Kwan O and Yuen Long. More information about HKSTP is available at www.hkstp.org
View source version on businesswire.com: https://www.businesswire.com/news/home/20210113005421/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
2PointZero Group Signals Global Scale With Revenue Surge to AED 21.9 Billion and Net Profit of AED 7.7 Billion in H1 202631.7.2026 13:42:00 CEST | Press release
Group revenue growth supported by stable gross profit margin of 29%, and adjusted EBITDA of AED 5.0 billionGlobal expansion milestones include the completed sale of TAQA stake, and the acquisition of Traverse Midstream Partners in North America, Baobab Group in Africa, and 60.8% of ISEM in ItalyTIME ranks the Group 36th on the World’s Growth Leaders list for 2026, highlighting market stability, operational scale and disciplined approach to capital 2PointZero Group (ADX: 2POINTZERO), a leading Abu Dhabi-based investment holding firm, announced its financial results for the first half of 2026, reporting revenue of AED 21.9 billion and delivering a Group Net Profit of AED 7.7 billion. This robust performance is reflected in the Group’s adjusted EBITDA, which reached AED 5.0 billion after excluding fair value changes and one-offs. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260731538982/en/ Samia Bouazza, CEO of 2PointZero (P
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
